Diabetes mellitus (DM) is a metabolic syndrome that’s spreading like an epidemic all through the world with none differentiation of races and ethnic teams and has grow to be the reason for loss of life worldwide. It’s characterised by excessive ranges of glucose within the blood and has differing kinds labeled on the premise of various pathophysiology.

Kind 1 diabetes or insulin-dependent diabetes is characterised by insulin insufficiency resulting from autoimmune dysfunction. Kind 2 diabetes or non-insulin-dependent diabetes outcomes from the mixture of resistance to insulin motion or/and insufficient insulin secretion. Gestational diabetes (GDM) is outlined as hyperglycemia resulting from insulin resistance throughout being pregnant.

Different sorts embrace the monogenic sort of DM resembling neonatal diabetes mellitus (NDM), maturity-onset diabetes of younger (MODY), and diabetes in metabolic syndrome. Diabetes is identified by standards given by American Diabetes Affiliation (ADA) for various checks like fasting plasma glucose take a look at and hemoglobin A1c take a look at.

It’s characterised by polydipsia, polyphagia, hyperglycemia, and glucosuria. Diabetes mellitus is managed by medicines however many research have confirmed that consumption of explicit meals results in decreased glucose ranges in diabetic sufferers.

The bioactive elements in these seeds like chlorogenic acid in sunflower seeds and secoisolariciresinol diglucosoid are concerned within the therapy of insulin resistance or insulin manufacturing. Seeds like sunflower and flax seeds have a job within the discount of glucose ranges and can be utilized to deal with sort 2 diabetes.

In numerous research, totally different quantities of those seed extracts have been consumed by rats and people and it resulted in higher glycemic management, which gives info that these seeds have anti-diabetic properties.

Sulfonylureas for Therapy of Periodontitis-Diabetes Comorbidity-Associated Issues: Killing Two Birds With One Stone

Periodontitis is without doubt one of the most prevalent oral inflammatory ailments resulting in tooth loss and oral well being issues in adults. Periodontitis primarily impacts periodontal tissue by affecting the host immune system and bone homeostasis. Furthermore, periodontitis is related to varied systemic ailments.

Diabetes is a metabolic illness with systemic results. Each periodontitis and diabetes are frequent inflammatory ailments, and comorbidity of two ailments is linked to exacerbation of the pathophysiology of each ailments. Since bacterial dysbiosis is principally accountable for periodontitis, antibiotics are extensively used medication to deal with periodontitis in clinics.

Nevertheless, the outcomes of antibiotic remedies in periodontitis are usually not passable. Due to this fact, the applying of anti-inflammatory medication together with antibiotics could possibly be a therapy choice for periodontitis-diabetes comorbidity. Anti-diabetic medication normally have anti-inflammatory properties and have proven useful results on periodontitis.

Sulfonylureas, insulin secretagogues, are the earliest and most generally used oral hypoglycemic medication used for type-2 diabetes. Research have discovered that sulfonylurea medication can play a sure position within the mitigation of periodontitis and irritation.

This text evaluations the consequences of sulfonylurea medication on the mitigation of periodontitis-diabetes comorbidity-related irritation, bone loss, and vascular development in addition to the concerned molecular mechanisms. We focus on the potential of a brand new utility of sulfonylureas (previous drug) to deal with periodontitis-diabetes comorbidity.

The Validity of the American Diabetes Affiliation’s Diabetes Danger Check in a Saudi Arabian Inhabitants

Introduction The prevalence of sort 2 diabetes (T2D) is rising worldwide. This examine aimed to evaluate the sensitivity and specificity of the American Diabetes Affiliation (ADA) and america Facilities for Illness Management and Prevention’s diabetes threat take a look at in figuring out Saudi Arabian sufferers prone to creating T2D.

Strategies We carried out a one-month cross-sectional examine that included sufferers older than 18 years who visited main care services for any well being concern in Riyadh Metropolis, Saudi Arabia. We used the Arabic language model of the ADA Prediabetes Danger Check questionnaire, a validated and dependable device, to gather information.

For this examine, we analyzed the information utilizing IBM SPSS Statistics for Home windows, model 24.0 (IBM Corp., Armonk, New York). Furthermore, we calculated sensitivity and specificity, constructive predictive values (PPV), destructive predictive worth (NPV), the realm beneath the curve (AUC), and Youden’s index.

Outcomes A complete of 180 individuals have been included within the examine (121 ladies and 59 males; imply age = 45 years). The ADA Prediabetes Danger Check sensitivity was 78.9, specificity was 82, PPV was 32, and NPV was 76. Youden’s index was 60.9 and the AUC was 0.6.

Conclusion The ADA prediabetes threat evaluation device is extremely delicate and particular for figuring out the illness. It’s a dependable and legitimate device that has not but been applied to a fantastic extent in Saudi Arabia. Due to this fact, future work ought to examine the device’s effectiveness in threat evaluation in extra native Saudi Arabian communities.

This cross-sectional analytical examine concerned sufferers with tbl2DM aged ≥ 18 years who used metformin for a minimum of three months. The serum VitB12 was quantified on a chemiluminescent enzyme immunoassay analyzer utilizing Cobas e 801 module, Roche, and VitB12 deficiency was outlined as serum VitB12 stage of ≤ 145 pmol/L. All information have been obtained from the sufferers’ digital medical data.

Muscle Infarction Following Fast Glycemic Management in a Affected person With Diabetes-Related Microvascular Illness

We report a case of a 40-year-old African male with a historical past of diabetes mellitus with a number of microvascular problems, having lately initiated insulin therapy with a speedy decline in glycosylated hemoglobin (HbA1c) focus. The affected person offered with a sudden onset of proper thigh ache and swelling not related to trauma. Blood work revealed elevated inflammatory markers.

AAV1-Luc Control Virus
AAV-321 50 ?L
EUR 1221.6
Description: Luciferase control virus of AAV serotype 1.

AAV3-Luc Control Virus
AAV-323 50 ?L
EUR 1221.6
Description: Luciferase control virus of AAV serotype 3.

AAV4-Luc Control Virus
AAV-324 50 ?L
EUR 1221.6
Description: Luciferase control virus of AAV serotype 4.

AAV5-Luc Control Virus
AAV-325 50 ?L
EUR 1221.6
Description: Luciferase control virus of AAV serotype 5.

AAV6-Luc Control Virus
AAV-326 50 ?L
EUR 1221.6
Description: Luciferase control virus of AAV serotype 6.

Lenti-hTERT Antisense virus
G201 10 ml
EUR 882

Lenti-hTERT-Neo Virus
G204 10 ml
EUR 973.2

Lenti-Myc T58A Virus
G217 10 ml
EUR 973.2

Lenti-p53 siRNA Virus
G219 10 ml
EUR 973.2

Lenti-Ras V12 Virus
G221 10 ml
EUR 973.2

Lenti-Rb siRNA Virus
G223 10 ml
EUR 973.2

NF-κB Reporter (Luc) - HCT116 Cell Line
60623 2 vials
EUR 1095
Description: NF-B luciferase reporter construct is stably integrated into the genome of HCT-116 cells. The
firefly luciferase gene is controlled by 4 copies of NF-κB response element located upstream of
the TATA promoter. Following activation by stimulants, endogenous NF-κB transcription factors
bind to the DNA response elements to induce transcription of the luciferase gene._x000D_The NF-κB-luciferase/HCT-116 cell line is suitable for monitoring the activity of NF-κB signaling
in response to stimulants such as the cytokines TNF and IL-1β, pathogen-associated
molecular pattern (PAMP) (i.e. flagellin) or endogenous damage-associated molecular pattern
(DAMP) molecules (i.e. NOD1 ligand) (see application references). It is also suitable for
establishing cell-based screens for inhibitors that target specific NF-κB stimulating molecules.
This cell line can be further modified to allow investigation of downstream NF-κB activities as a
result of targeted genetic mutation(s).

Foxp3 Reporter (Luc) - Jurkat Recombinant Cell Line
60628 2 vials
EUR 7645
Description: Human Foxp3 luciferase reporter construct is stably integrated into the genome of Jurkat T- cells. The firefly luciferase gene is controlled by a human Foxp3 promoter and an enhancer-like conserved noncoding sequence upstream of the Foxp3 promoter.

NF-κB reporter (Luc) - HEK293 Cell line
60650 2 vials
EUR 1365
Description: The NF-κB reporter (Luc) HEK293 cell line is designed to monitor nuclear factor Kappa B (NF-κB) activity. It contains a firefly luciferase gene driven by four copies of the NF-κB response element located upstream of the minimal TATA promoter. After activation by pro-inflammatory cytokines or agonists of lymphokine receptors, endogenous NF-κB transcription factors bind to the DNA response elements, inducing transcription of the luciferase reporter gene. The cell line has been functionally validated in response to human TNF-α, IL-1β, and IL-17.

STAT5 Reporter (Luc) - Ba/F3 Cell line
79772 2 vials
EUR 2275
Description: The STAT5 Reporter (Luc)-Ba/F3 cell line is designed for monitoring STAT5 signal transduction pathways. It contains a firefly luciferase gene driven by the STAT5 response element located upstream of the minimal TATA promoter. After activation by cytokines or growth factors, endogenous STAT5 binds to the DNA response elements, inducing transcription of the luciferase reporter gene.

STAT3 Reporter (Luc) - HEK293 Cell line (Puromycin)
79800-P 2 vials
EUR 3730
Description: The STAT3 Reporter (Luc)-HEK293 cell line is designed for monitoring STAT3 signal transduction pathway. It contains a firefly luciferase gene driven by STAT3 response elements located upstream of the minimal TATA promoter. After activation by cytokines and growth factors, endogenous STAT3 binds to the DNA response elements, inducing transcription of the luciferase reporter gene.

IRF Reporter (Luc) - THP-1 Cell line
79858 2 vials
EUR 1810
Description: The Interferon Regulatory Factor (IRF) reporter (Luc)-THP-1 cell line is designed to study the activation and signaling of Cytosolic DNA Sensors (CDS) in human monocytic cell line THP-1. It contains a firefly luciferase gene driven by multimerized ISRE (Interferon Stimulated Response Element) located upstream of the minimal TATA promoter. _x000D_The cGAS-STING pathway acts to detect cytosolic DNA and induce an immune response. Briefly, upon binding DNA, the protein cGAS (cyclic GMP-AMP Synthase) triggers reaction of GTP and ATP to form cGAMP. cGAMP binds to STING (Stimulator of Interferon Genes) which triggers phosphorylation of IRF3 via TBK1. IRF3 can then bind to interferon-stimulated responsive elements (ISRE) in the nucleus and leads to IFN-α/β production. The IRF reporter (Luc)-THP-1 cell line is highly responsive to STING and CDS ligands.

Bald Lentiviral Pseudovirion (Luc-eGFP Dual Reporter)
79988 500 µl x 2
EUR 795
Description: The bald lentiviral pseudovirion was produced without envelope glycoproteins such as VSV-G or SARS-CoV-2 spike. It contains a firefly luciferase and eGFP cassette (Luc-P2A-eGFP) as the reporters, driven by a CMV promoter. The bald lentiviral pseudovirion can serve as a negative control when studying virus entry initiated by specific interactions between virus particles and receptors._x000D_

Lenti-Bmi1 Virus, High Titer
LV608 5 x 20 ul
EUR 1825.2

Lenti-CDK4 Virus, High Titer
LV609 5 x 20 ul
EUR 1825.2

Lenti-hTERT Virus, High Titer
LV615 5 x 20 ul
EUR 1825.2

Lenti-EF1α-hTERT Virus
G706 10 ml
EUR 1094.4

PAI-1 Reporter (Luc) - Mv1 Lu Cell Line
60544 2 vials
EUR 3595
Description: PAI-1 Reporter (Luc)-Mv1 Lu cell line is designed for monitoring transforming growth factor β (TGF-β)-induced plasminogen activator inhibitor-1 (PAI-1) expression. Transforming growth factor-β (TGF-β) is a potent regulator of cellular differentiation, proliferation, migration, and protein expression._x000D__x000D_PAI-1 Reporter (Luc) -Mv1 Lu cell line contains a firefly luciferase gene under the control of PAI-1 responsive elements stably integrated into Mv1 Lu (NBL-7) cells, showing TGF-β pathway response. This cell line is validated for the TGF-β response to the induction of PAI-1 gene expression through luciferase activity. _x000D_

NF-κB Reporter (Luc) - CHO-K1 Cell Line
60622 2 vials
EUR 1095
Description: An NF-κB luciferase reporter construct is stably integrated into the genome of CHO-K1 cells. The firefly luciferase gene is controlled by the NF-κB response element located upstream of the TATA promoter. Following activation by stimulants, endogenous NF-κB transcription factors bind to the DNA response elements to induce transcription of the luciferase gene._x000D_The NF-κB-luciferase / CHO-K1 cell line is suitable for monitoring the activity of NF-κB transcription factor through luminescence readout.). This cell line responds to human cytokine IL-1β, responds moderately to human TNF, and does not respond to human IFN-λ (2 µg/ml). Reducing the amount of serum during incubation period may increase the sensitivity to cytokines. Since CHO-K1 cells do not express endogenous human proteins, this cell line provides an excellent platform to enable exogenous expression of a protein of interest to study its downstream effect on NF-κB signaling.

NF-κB Reporter (Luc) - A549 Stable Cell Line
60625 2 vials
EUR 1915
Description: NF-κB luciferase reporter construct is stably integrated into the genome of A549 cells. The firefly luciferase gene is controlled by 4 copies of NF-κB response element located upstream of the TATA promoter. Following activation by stimulants, endogenous NF-κB transcription factors bind to the DNA response elements to induce transcription of the luciferase gene.

NF-κB-Luciferase Reporter (Luc) - Jurkat Cell Line
60651 2 vials
EUR 2340
Description: NF-κB luciferase reporter construct is stably integrated into the genome of Jurkat T- cells. The firefly luciferase gene is controlled by 4 copies of NF-kB response element located upstream of the TATA promoter. Following activation by stimulants, endogenous NF-κB transcription factors bind to the DNA response elements to induce transcription of the luciferase gene.

Spike (B.1.429 Variant) Pseudotyped Lentivirus (Luc Reporter)
78172-1 100 µl
EUR 835
Description: The Spike (B.1.429 Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.429 Variant Spike (Genbank Accession #QHD43416.1 with B.1.429 variant mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.429 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.429 variant in a Biosafety Level 2 facility.Spike Mutations in B.1.429 Variant: S13I
W152C
L452R
D614G

Spike (B.1.429 Variant) Pseudotyped Lentivirus (Luc Reporter)
78172-2 500 µl x 2
EUR 4195
Description: The Spike (B.1.429 Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.429 Variant Spike (Genbank Accession #QHD43416.1 with B.1.429 variant mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.429 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.429 variant in a Biosafety Level 2 facility.Spike Mutations in B.1.429 Variant: S13I
W152C
L452R
D614G

Spike (B.1.617 Variant) Pseudotyped Lentivirus (Luc Reporter)
78204-1 100 µl
EUR 835
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617 (Kappa, Delta lineage) was identified in India in the spring of 2021. This variant has a number of mutations that allow the virus to spread more easily and quickly than other variants. The Spike (B.1.617 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.617 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617 variant in a Biosafety Level 2 facility. 

Spike (B.1.617 Variant) Pseudotyped Lentivirus (Luc Reporter)
78204-2 500 µl x 2
EUR 4195
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617 (Kappa, Delta lineage) was identified in India in the spring of 2021. This variant has a number of mutations that allow the virus to spread more easily and quickly than other variants. The Spike (B.1.617 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.617 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617 variant in a Biosafety Level 2 facility.

Spike (B.1.617.1 Variant) Pseudotyped Lentivirus (Luc Reporter)
78205-1 100 µl
EUR 835
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617.1 (also known as the Kappa Variant) was identified in India in the spring of 2021. This variant has a number of mutations that allow the virus to spread more easily and quickly than other variants. The Spike (B.1.617.1 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.617.1 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617.1 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617.1 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617.1 variant in a Biosafety Level 2 facility. Spike Mutations in B.1.617.1 Variant:G142DE154KL452RE484QD614GP681RQ1071H

Spike (B.1.617.1 Variant) Pseudotyped Lentivirus (Luc Reporter)
78205-2 500 µl x 2
EUR 4195
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617.1 (also known as the Kappa Variant) was identified in India in the spring of 2021. This variant has a number of mutations that allow the virus to spread more easily and quickly than other variants. The Spike (B.1.617.1 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.617.1 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617.1 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617.1 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617.1 variant in a Biosafety Level 2 facility. Spike Mutations in B.1.617.1 Variant:G142DE154KL452RE484QD614GP681RQ1071H

Spike (B.1.618 Variant) Pseudotyped Lentivirus (Luc Reporter)
78206-1 100 µl
EUR 835
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.618 was identified in India in the spring of 2021. This variant has a number of mutations that allow the virus to spread more easily and quickly than other variants. The Spike (B.1.618 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.618 Variant Spike (Genbank Accession #QHD43416.1 with B.1.618 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.618 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.618 variant in a Biosafety Level 2 facility. Spike Mutations in B.1.618 Variant:Y145delH146delE484KD614G

Spike (B.1.618 Variant) Pseudotyped Lentivirus (Luc Reporter)
78206-2 500 µl x 2
EUR 4195
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.618 was identified in India in the spring of 2021. This variant has a number of mutations that allow the virus to spread more easily and quickly than other variants. The Spike (B.1.618 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.618 Variant Spike (Genbank Accession #QHD43416.1 with B.1.618 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.618 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.618 variant in a Biosafety Level 2 facility. Spike Mutations in B.1.618 Variant:Y145delH146delE484KD614G

Spike (B.1.617.2 Variant) Pseudotyped Lentivirus (Luc Reporter)
78215-1 100 µl
EUR 900
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617.2 (also known as the Delta Variant) was identified in India in the spring of 2021. This variant has a number of mutations that increase morbidity and mortality and allow the virus to spread more easily and quickly than other variants.The Spike (B.1.617.2 Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.617.2 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617.2 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617.2 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617.2 variant in a Biosafety Level 2 facility.

Spike (B.1.617.2 Variant) Pseudotyped Lentivirus (Luc Reporter)
78215-2 500 µl x 2
EUR 4510
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617.2 (also known as the Delta Variant) was identified in India in the spring of 2021. This variant has a number of mutations that increase morbidity and mortality and allow the virus to spread more easily and quickly than other variants.The Spike (B.1.617.2 Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.617.2 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617.2 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617.2 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617.2 variant in a Biosafety Level 2 facility.

Spike (SARS-CoV-1) Pseudotyped Lentivirus (Luc Reporter)
78614-1 100 µl
EUR 860
Description: Severe acute respiratory syndrome (SARS) was the first new infectious disease identified in the twenty-first century. It is a viral respiratory disease caused by severe acute respiratory syndrome coronavirus (SARS-CoV-1). The first known cases occurred in November 2002, and the syndrome caused the 2002-2004 SARS outbreak. Since 2004, no cases of SARS-CoV-1 have been reported worldwide. A virus very similar to SARS-CoV-1 was discovered in late 2019. This virus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is the causative pathogen of COVID-19, the spread of which started the COVID-19 pandemic.SARS-CoV-1 attaches to the host cell surface before entering the cell. The Spike protein on the virus recognizes and binds to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of human airway epithelia as well as lung parenchyma. Drugs targeting the interaction between the Spike protein of SARS-CoV-1 and ACE2 may offer protection against the viral infection.The Spike (SARS-CoV-1) Pseudotyped Lentiviruses were produced with SARS-CoV-1 Spike (Genbank Accession #YP_009825051.1) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-1) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-1 in a cellular context, using a Biosafety Level 2 facility.The Spike (SARS-CoV-1) Pseudotyped Lentiviruses has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience #79951).

Spike (SARS-CoV-1) Pseudotyped Lentivirus (Luc Reporter)
78614-2 500 µl x 2
EUR 4320
Description: Severe acute respiratory syndrome (SARS) was the first new infectious disease identified in the twenty-first century. It is a viral respiratory disease caused by severe acute respiratory syndrome coronavirus (SARS-CoV-1). The first known cases occurred in November 2002, and the syndrome caused the 2002-2004 SARS outbreak. Since 2004, no cases of SARS-CoV-1 have been reported worldwide. A virus very similar to SARS-CoV-1 was discovered in late 2019. This virus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is the causative pathogen of COVID-19, the spread of which started the COVID-19 pandemic.SARS-CoV-1 attaches to the host cell surface before entering the cell. The Spike protein on the virus recognizes and binds to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of human airway epithelia as well as lung parenchyma. Drugs targeting the interaction between the Spike protein of SARS-CoV-1 and ACE2 may offer protection against the viral infection.The Spike (SARS-CoV-1) Pseudotyped Lentiviruses were produced with SARS-CoV-1 Spike (Genbank Accession #YP_009825051.1) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-1) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-1 in a cellular context, using a Biosafety Level 2 facility.The Spike (SARS-CoV-1) Pseudotyped Lentiviruses has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience #79951).

NF-κB reporter (Luc) - NIH/3T3 Cell line
79469 2 vials
EUR 1900
Description: The NF-κB reporter (Luc)-NIH/3T3 cell line is designed for monitoring nuclear factor Kappa B (NF-κB) signal transduction pathways. It contains a firefly luciferase gene driven by four copies of the NF-κB response element located upstream of the minimal TATA promoter. After activation by pro-inflammatory cytokines or stimulants of lymphokine receptors, endogenous NF-κB transcription factors bind to the DNA response elements, inducing transcription of the luciferase reporter gene.

NF- κB Reporter (Luc) - THP-1 Cell Line
79645 2 vials
EUR 1900
Description: The NF-κB reporter (Luc)-THP-1 cell line is designed for monitoring nuclear factor Kappa B (NF-κB) signal transduction pathways. It contains a firefly luciferase gene driven by four copies of the NF-κB response element located upstream of the minimal TATA promoter. After activation by pro-inflammatory cytokines or stimulants of lymphokine receptors, endogenous NF-κB transcription factors bind to the DNA response elements, inducing transcription of the luciferase reporter gene.

STAT5 Reporter (Luc)- U937 Cell Line (GM-CSF)
79941 2 vials
EUR 1980
Description: The STAT5 Reporter (Luc)-U937 cell line is designed for monitoring STAT5 signal transduction pathway in the U937 cell line. It contains a firefly luciferase gene driven by the STAT5 response element located upstream of the minimal TATA promoter. After activation by GM-CSF, endogenous STAT5 binds to the DNA response elements, inducing transcription of the luciferase reporter gene.

NF- κB Reporter (Luc) - Raw 264.7 Cell line
79978 2 vials
EUR 2045
Description: The NF-κB reporter (Luc)-Raw 264.7 cell line is designed for monitoring nuclear factor Kappa B (NF-κB) signal transduction pathways. It contains a firefly luciferase gene driven by four copies of the NF-κB response element located upstream of the minimal TATA promoter. After activation by pro-inflammatory cytokines or stimulants of lymphokine receptors, endogenous NF-κB transcription factors bind to the DNA response elements, inducing transcription of the luciferase reporter gene.

Steady-Luc Firefly HTS Assay Kit (10x100 ml)
30028-3 1KIT
EUR 3774
Description: Minimum order quantity: 1 unit of 1KIT

Rrad/ Rat Rrad ELISA Kit
ELI-14921r 96 Tests
EUR 1063.2

Human BM88 Differentiation Reporter (pGreenZeo, Virus)
SR10021VA-1 >2 x 10^6 IFUs
EUR 906

Mouse Camk2a Differentiation Reporter (pGreenZeo, Virus)
SR10022VA-1 >2 x 10^6 IFUs
EUR 906

Mouse GAD67 Differentiation Reporter (pGreenZeo, Virus)
SR10023VA-1 >2 x 10^6 IFUs
EUR 906

Rat NSE Differentiation Reporter (pGreenZeo, Virus)
SR10024VA-1 >2 x 10^6 IFUs
EUR 906

Mouse MBP Differentiation Reporter (pGreenZeo, Virus)
SR10026VA-1 >2 x 10^6 IFUs
EUR 906

Human Opsin Differentiation Reporter (pGreenZeo, Virus)
SR10027VA-1 >2 x 10^6 IFUs
EUR 906

Human Insulin Differentiation Reporter (pGreenZeo, Virus)
SR10028VA-1 >2 x 10^6 IFUs
EUR 906

Human LCK Differentiation Reporter (pGreenZeo, Virus)
SR10032VA-1 >2 x 10^6 IFUs
EUR 906

Rat Nestin Differentiation Reporter (pGreenZeo, Virus)
SR10034VA-1 >2 x 10^6 IFUs
EUR 906

Human Nestin Differentiation Reporter (pGreenZeo, Virus)
SR10035VA-1 >2 x 10^6 IFUs
EUR 906

Mouse ALBP Differentiation Reporter (pGreenZeo, Virus)
SR10036VA-1 >2 x 10^6 IFUs
EUR 906

Human NGN3 Differentiation Reporter (pGreenZeo, Virus)
SR10037VA-1 >2 x 10^6 IFUs
EUR 906

Human PDX1 Differentiation Reporter (pGreenZeo, Virus)
SR10039VA-1 >2 x 10^6 IFUs
EUR 906

Human Osteocalcin Differentiation Reporter (pGreenZeo, Virus)
SR1003VA-1 >2 x 10^6 IFUs
EUR 906

Mouse PDX1 Differentiation Reporter (pGreenZeo, Virus)
SR10040VA-1 >2 x 10^6 IFUs
EUR 906

Human MAP2 Differentiation Reporter (pGreenZeo, Virus)
SR10047VA-1 >2 x 10^6 IFUs
EUR 906

Human FABP7 Differentiation Reporter (pGreenZeo, Virus)
SR10048VA-1 >2 x 10^6 IFUs
EUR 906

Human ACTC Differentiation Reporter (pGreenZeo, Virus)
SR10049VA-1 >2 x 10^6 IFUs
EUR 906

Human B29 Differentiation Reporter (pGreenZeo, Virus)
SR1004VA-1 >2 x 10^6 IFUs
EUR 906

Mouse Myogenin Differentiation Reporter (pGreenZeo, Virus)
SR10050VA-1 >2 x 10^6 IFUs
EUR 906

Human GFAP Differentiation Reporter (pRedZeo, Virus)
SR10051VA-1 >2 x 10^6 IFUs
EUR 906

Mouse B29 Differentiation Reporter (pGreenZeo, Virus)
SR1005VA-1 >2 x 10^6 IFUs
EUR 906

Human NKX2.5 Differentiation Reporter (pGreenZeo, virus)
SR10067VA-1 >2 x 10^6 IFUs
EUR 906

Mouse CD8 Differentiation Reporter (pGreenZeo, Virus)
SR1006VA-1 >2 x 10^6 IFUs
EUR 906

Mouse CD68 Differentiation Reporter (pGreenZeo, Virus)
SR1008VA-1 >2 x 10^6 IFUs
EUR 906

Human CD2 Differentiation Reporter (pGreenZeo, Virus)
SR1009VA-1 >2 x 10^6 IFUs
EUR 906

Oct4 CR4-pGreenFire Response Reporter (virus)
SR20070-VA-1 >2 x 10^6 IFUs
EUR 882

Mouse Actc Differentiation Reporter (pGreenZeo, Virus)
SR10010VA-1 >2 x 10^6 IFUs
EUR 906

Human Tnnt2 Differentiation Reporter (pGreenZeo, Virus)
SR10012VA-1 >2 x 10^6 IFUs
EUR 906

Mouse Tnnt2 Differentiation Reporter (pGreenZeo, Virus)
SR10013VA-1 >2 x 10^6 IFUs
EUR 906

Mouse SM22a Differentiation Reporter (pGreenZeo, Virus)
SR10014VA-1 >2 x 10^6 IFUs
EUR 906

Human GFAP Differentiation Reporter (pGreenZeo, Virus)
SR10015VA-1 >2 x 10^6 IFUs
EUR 906

Mouse GFAP Differentiation Reporter (pGreenZeo, Virus)
SR10016VA-1 >2 x 10^6 IFUs
EUR 906

Human CD11b Differentiation Reporter (pGreenZeo, Virus)
SR10017VA-1 >2 x 10^6 IFUs
EUR 906

Mouse EMR1 Differentiation Reporter (pGreenZeo, Virus)
SR10018VA-1 >2 x 10^6 IFUs
EUR 906

Mouse Col2a1 Differentiation Reporter (pGreenZeo, Virus)
SR1001VA-1 >2 x 10^6 IFUs
EUR 906

Mouse CD44 Differentiation Reporter (pGreenZeo, Virus)
SR10020VA-1 >2 x 10^6 IFUs
EUR 906

NF-kB/293/GFP-Luc Transcriptional Reporter Cell Line
TR860A-1 >2 x 10^6 cells
EUR 3915.6

Myc Reporter (Luc) - HCT116 Cell Line (Myc Signaling Pathway)
60520 2 vials
EUR 2175
Description: The Myc Reporter - HCT116 cell line contains the firefly luciferase gene under the control of Myc responsive elements stably integrated into HCT116 cells, a human colon cancer cell line. HCT116 contains a mutated beta-catenin which leads to the accumulation of β-catenin and constitutive activation of downstream Myc that induces the expression of Myc luciferase reporter. The cell line is validated for the inhibition of the expression of Myc luciferase reporter.

GITR / NF-κB-Luciferase Reporter (Luc) - Jurkat Cell Line
60546 2 vials
EUR 10175
Description: This cell line expresses a surface human GITR (glucocorticoid-induced TNFR family related gene; TNFRSF18; CD357) and an NF-κB luciferase reporter construct that are stably integrated into the genome of Jurkat T-cells. The firefly luciferase gene is controlled by 4 copies of NF-κB response element located upstream of the TATA promoter. Following activation by stimulants, endogenous NF-κB transcription factors bind to the DNA response elements to induce transcription of the luciferase gene. The cells have been validated using purified human GITRL and anti-GITR neutralizing antibody.

CD40/NF-κB Reporter (Luc) - HEK293 Stable Cell Line
60626 2 vials
EUR 6825
Description: Recombinant HEK293 cell line expressing full length human CD40 (Tumor necrosis factor receptor superfamily member 5; TNFRSF5). Expression is confirmed by real-time qPCR and Western Blot. This NF-κB luciferase reporter construct is stably integrated into the genome. The firefly luciferase gene is controlled by 4 copies of NF-κB response element located upstream of the TATA promoter. Following activation by human CD40 ligand, NF-κB transcription factor binds to the DNA response elements to induce transcription of the luciferase gene. _x000D_

Spike (SARS-CoV-2, D614G) Pseudotyped Lentivirus (Luc Reporter)
78028-1 100 µl
EUR 900
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein and ACE2 may offer protection against the viral infection. A SARS-CoV-2 variant carrying the spike protein amino acid change D614G has become the most prevalent form in the global pandemic.
The SARS-CoV-2 Spike D614G Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1; with D614G mutation) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The SARS-CoV-2 Spike D614G pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_

Spike (SARS-CoV-2, D614G) Pseudotyped Lentivirus (Luc Reporter)
78028-2 500 µl x 2
EUR 4510
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein and ACE2 may offer protection against the viral infection. A SARS-CoV-2 variant carrying the spike protein amino acid change D614G has become the most prevalent form in the global pandemic.
The SARS-CoV-2 Spike D614G Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1; with D614G mutation) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The SARS-CoV-2 Spike D614G pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_

GLP-1R/CRE (Luc) Reporter - HEK293 Recombinant Cell Line
78176 2 vials
EUR 10105
Description: Recombinant HEK293 cells expressing firefly luciferase gene under the control of cAMP response element (CRE) with constitutive expression of human GLP-1R (Glucagon-like peptide 1 receptor; accession number BC113493)._x000D_GLP-1R, a member of the class B family of G protein-coupled receptors (GPCRs) primarily found in pancreatic β cells, is activated by a peptide hormone, glucagon-like peptide 1 (GLP-1) that is secreted from intestinal L-cells after nutrient ingestion. GLP-1R plays an important role in controlling blood sugar level by enhancing glucose-stimulated insulin secretion, so various research efforts have focused on the regulation of the GLP-1R mediated signaling pathway as a therapeutic approach to diabetes.

Spike (B.1.1.529, Omicron Variant) Pseudotyped Lentivirus (Luc Reporter)
78348-1 100 µl
EUR 900
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.1.529 (also known as the Omicron Variant) was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants.The Spike (B.1.1.529 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.1.529 Variant Spike (Genbank Accession #QHD43416.1 with B.1.1.529 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.1.529 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.1.529 variant in a Biosafety Level 2 facility.The Spike Omicron pseudovirus has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience, #79951).

Spike (B.1.1.529, Omicron Variant) Pseudotyped Lentivirus (Luc Reporter)
78348-2 500 µl x 2
EUR 4510
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.1.529 (also known as the Omicron Variant) was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants.The Spike (B.1.1.529 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.1.529 Variant Spike (Genbank Accession #QHD43416.1 with B.1.1.529 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.1.529 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.1.529 variant in a Biosafety Level 2 facility.The Spike Omicron pseudovirus has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience, #79951).

Lenti-Myc T58A Virus, High Titer
LV618 5 x 20 ul
EUR 1825.2

Lenti-p53 siRNA Virus, High Titer
LV619 5 x 20 ul
EUR 1825.2

Lenti-Ras V12 Virus, High Titer
LV620 5 x 20 ul
EUR 1825.2

Lenti-Rb siRNA Virus, High Titer
LV621 5 x 20 ul
EUR 1825.2

Lenti-hTERT-Neo Virus, High Titer
LV622 5 x 20 ul
EUR 1825.2

Lenti-HPV-16 E6/E7 Virus
G268 10 ml
EUR 882

Rrad 3'UTR Luciferase Stable Cell Line
TU219725 1.0 ml Ask for price

Rrad 3'UTR GFP Stable Cell Line
TU168183 1.0 ml Ask for price

Rrad 3'UTR GFP Stable Cell Line
TU269725 1.0 ml Ask for price

Rrad 3'UTR Luciferase Stable Cell Line
TU118183 1.0 ml Ask for price

RRAD 3'UTR GFP Stable Cell Line
TU072380 1.0 ml
EUR 1672.8

RRAD 3'UTR Luciferase Stable Cell Line
TU022380 1.0 ml
EUR 1672.8

RRAD Antibody
CSB-PA233809-100ul 100ul
EUR 379.2
Description: A polyclonal antibody against RRAD. Recognizes RRAD from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC, IF;WB:1:500-1:3000, IHC:1:50-1:100, IF:1:100-1:500

RRAD Antibody
1-CSB-PA248209
  • EUR 380.40
  • EUR 292.80
  • 100ul
  • 50ul
Description: A polyclonal antibody against RRAD. Recognizes RRAD from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:1000-1:5000, IHC:1:25-1:100

RRAD Antibody
1-CSB-PA003910
  • EUR 266.40
  • EUR 234.00
  • 100ug
  • 50ug
Description: A polyclonal antibody against RRAD. Recognizes RRAD from Human. This antibody is Unconjugated. Tested in the following application: WB, IHC, IF, ELISA;WB:1/500-1/2000.IHC:1/100-1/300.IF:1/200-1/1000.ELISA:1/20000

RRAD siRNA
20-abx932133
  • EUR 661.20
  • EUR 878.40
  • 15 nmol
  • 30 nmol

RRAD Antibody
1-CSB-PA779820
  • EUR 380.40
  • EUR 292.80
  • 100ul
  • 50ul
Description: A polyclonal antibody against RRAD. Recognizes RRAD from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:2000-1:5000, IHC:1:50-1:200

RRAD antibody
70R-50359 100 ul
EUR 292.8
Description: Purified Polyclonal RRAD antibody

RRAD antibody
70R-5797 50 ug
EUR 560.4
Description: Rabbit polyclonal RRAD antibody raised against the middle region of RRAD

RRAD antibody
70R-5798 50 ug
EUR 560.4
Description: Rabbit polyclonal RRAD antibody raised against the middle region of RRAD

RRAD Peptide
43-008P 0.1 mg
EUR 405.6
Description: RRAD Peptide

RRAD Antibody
37229-100ul 100ul
EUR 302.4

RRAD Antibody
R34275-100UG 100 ug
EUR 399

RRAD Antibody
CSB-PA233809- each
EUR 402
Description: A polyclonal antibody against RRAD. Recognizes RRAD from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC, IF;WB:1:500-1:3000, IHC:1:50-1:100, IF:1:100-1:500

GR-GAL4 Reporter (Luc)-HEK293 Cell Line (Glucocorticoid Receptor Pathway)
60655 2 vials
EUR 2275
Description: The Glucocorticoid Receptor Pathway GAL4 Reporter (Luc) - HEK293 Cell Line contains a_x000D_firefly luciferase gene under the control of glucocorticoid receptor ligand binding domain that is_x000D_fused to the DNA binding domain (DBD) of GAL4 (GAL4 DBD-GR) stably integrated into_x000D_HEK293 cells. This fusion construct activates firefly luciferase expression under the control of a_x000D_multimerized GAL4 upstream activation sequence (UAS). This allows for specific detection of_x000D_glucocorticoid-induced activation of the glucocorticoid receptor without the need for individual_x000D_transcriptional targets and with low cross-reactivity for other nuclear receptor pathways. This cell_x000D_line is validated for response to stimulation of dexamethasone and to the treatment with_x000D_mifepristone, an inhibitor of the glucocorticoid signaling pathway.

Spike (SARS-CoV-2, UK Variant) Pseudotyped Lentivirus (Luc Reporter)
78112-1 100 µl
EUR 875
Description: The Spike (SARS-CoV-2, UK variant) Pseudotyped Lentivirus were produced with SARS-CoV-2 UK Variant Spike (Genbank Accession #QHD43416.1 with UK variant mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-2, UK variant) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 UK variant in a Biosafety Level 2 facility._x000D_

Spike (SARS-CoV-2, UK Variant) Pseudotyped Lentivirus (Luc Reporter)
78112-2 500 µl x 2
EUR 4405
Description: The Spike (SARS-CoV-2, UK variant) Pseudotyped Lentivirus were produced with SARS-CoV-2 UK Variant Spike (Genbank Accession #QHD43416.1 with UK variant mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-2, UK variant) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 UK variant in a Biosafety Level 2 facility._x000D_

Spike (B.1.617.2.1; Delta Plus Variant) Pseudotyped Lentivirus (Luc Reporter)
78218-1 100 µl
EUR 835
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617.2.1 (also known as the Delta Plus Variant) was identified in India in the spring of 2021. This variant has a number of mutations that increase morbidity and mortality and allow the virus to spread more easily and quickly than other variants.The Spike (B.1.617.2.1 Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.617.2.1 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617.2.1 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G.  Compared to the Delta variant (B.1.617.2), variant Delta Plus has an additional mutation, K417N. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617.2.1 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617.2.1 variant in a Biosafety Level 2 facility.

Spike (B.1.617.2.1; Delta Plus Variant) Pseudotyped Lentivirus (Luc Reporter)
78218-2 500 µl x 2
EUR 4195
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617.2.1 (also known as the Delta Plus Variant) was identified in India in the spring of 2021. This variant has a number of mutations that increase morbidity and mortality and allow the virus to spread more easily and quickly than other variants.The Spike (B.1.617.2.1 Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.617.2.1 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617.2.1 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G.  Compared to the Delta variant (B.1.617.2), variant Delta Plus has an additional mutation, K417N. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617.2.1 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617.2.1 variant in a Biosafety Level 2 facility.

GAS Reporter (Luc) - HeLa Cell Line (IFNγ/JAK/STAT1 Pathway)
79041 2 vials
EUR 1810
Description: The GAS reporter (Luc)-HeLa cell line is designed to monitor the activity of interferon gamma-induced signal transduction pathways in cultured cells by measuring activated STAT1 homodimers. It contains a firefly luciferase gene driven by three copies of the interferon gamma-activated sites (GAS) located upstream of the minimal TATA promoter. IFNγ first binds to a heterodimeric receptor consisting of two chains, IFNGR1 and IFNGR2, causing its dimerization and the activation of specific Janus family kinases (JAK1 and JAK2). Two STAT1 molecules associate with this ligand-activated receptor complex and are activated by phosphorylation to form active homodimer. The active STAT1 homodimers translocate to the nucleus where they bind interferon gamma-activated sites (GAS) in the promoter of IFNγ inducible genes, including luciferase reporter gene.

Spike(SARS-CoV-2) Pseudotyped Lentivirus (Luc-eGFP Dual Reporter)
79982-1 100 µl
EUR 1075
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection._x000D_
The SARS-CoV-2 Spike Pseudotyped Lentivirus (Luc-eGFP dual reporter) were produced by replacing the VSV-G fusion glycoprotein with SARS-CoV-2 Spike protein (Genbank Accession #QHD43416.1) as a surrogate viral envelope protein. These pseudovirions also contain a firefly luciferase and eGFP cassette (Luc-P2A-eGFP) driven by a CMV promoter. The luciferase and eGFP are coexpressed under the CMV promoter in the transduced cells. Therefore, the Spike-mediated entry into the target cell can be conveniently measured via luciferase reporter activity or eGFP expression. The SARS-CoV-2 Spike pseudotyped lentivirus can be used in a cellular assay to measure the activity of neutralizing antibody against SARS-CoV-2._x000D_

Spike(SARS-CoV-2) Pseudotyped Lentivirus (Luc-eGFP Dual Reporter)
79982-2 500 µl x 2
EUR 8110
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection._x000D_
The SARS-CoV-2 Spike Pseudotyped Lentivirus (Luc-eGFP dual reporter) were produced by replacing the VSV-G fusion glycoprotein with SARS-CoV-2 Spike protein (Genbank Accession #QHD43416.1) as a surrogate viral envelope protein. These pseudovirions also contain a firefly luciferase and eGFP cassette (Luc-P2A-eGFP) driven by a CMV promoter. The luciferase and eGFP are coexpressed under the CMV promoter in the transduced cells. Therefore, the Spike-mediated entry into the target cell can be conveniently measured via luciferase reporter activity or eGFP expression. The SARS-CoV-2 Spike pseudotyped lentivirus can be used in a cellular assay to measure the activity of neutralizing antibody against SARS-CoV-2._x000D_

Mouse Alpha-Tubulin Differentiation Reporter (pGreenZeo, Virus)
SR10025VA-1 >2 x 10^6 IFUs
EUR 906

Human SPP-1 Differentiation Reporter (pGreenZeo, Virus)
SR1002VA-1 >2 x 10^6 IFUs
EUR 906

Human Keratin 14 Differentiation Reporter (pGreenZeo, Virus)
SR10038VA-1 >2 x 10^6 IFUs
EUR 906

Human Doublecortin (DCX) Differentiation Reporter (pGreenZeo, Virus)
SR10041VA-1 >2 x 10^6 IFUs
EUR 906

Human HLA-DRa Differentiation Reporter (pGreenZeo, Virus)
SR1007VA-1 >2 x 10^6 IFUs
EUR 906

Human MLC-2v Differentiation Reporter (pGreenZeo, Virus)
SR10011VA-1 >2 x 10^6 IFUs
EUR 906

Human GFAP Differentiation Reporter (pGreenZeo, Virus) Puro
SR10015VA-P >2 x 10^6 IFUs
EUR 906

Mouse IBA-1 Differentiation Reporter (pGreenZeo, Virus)
SR10019VA-1 >2 x 10^6 IFUs
EUR 906

Lenti-EF1α-hTERT Virus, High Titer
LV616 5 x 20 ul
EUR 2068.8
A presumptive prognosis of pyomyositis was made and the affected person was handled with intravenous antibiotics with no enchancment. Diabetic muscle infarction was then thought of and confirmed by magnetic resonance imaging of the affected thigh. As with retinopathy and neuropathy deterioration which were described as secondary to an aggressive glycemic management, it’s doable that muscle myonecrosis could have been consequent to the speedy HbA1c normalization.
Therapeutic Effect of Sunflower Seeds and Flax Seeds on Diabetes

RELATED ARTICLESMORE FROM AUTHOR

LEAVE A REPLY

Please enter your comment!
Please enter your name here